|
|
|
|
|
|
|
¾àÇ°°Ë»ö |
|
ºÎÀÛ¿ë ¹× ´ëó¹ý |
|
|
|
|
|
|
|
¹ÙÀÌÆ÷ÁöÁ¤10/160mg Biforge Tab. 10/160mg
|
Àü¹®ÀǾàÇ° | ±Þ¿©
|
|
|
|
|
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàÇ° ÀÎÅÍ³Ý ÆǸŸ¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
Àü¹®/ÀÏ¹Ý |
Àü¹®
|
|
|
¹àÀº ³ë¶õ»öÀÇ ´Þ°¿Çü Çʸ§ÄÚÆÃÁ¤ |
|
|
|
|
|
Á¦Á¶È¸»ç |
Àϵ¿Á¦¾à(ÁÖ)
|
ÆǸÅȸ»ç |
Àϵ¿Á¦¾à(ÁÖ)
|
Çã°¡Á¤º¸ |
Á¤»ó
(2013.07.29)
|
BIT ¾àÈ¿ºÐ·ù |
Ä®½·Ã¤³Î±æÇ×Á¦ / ¾ÈÁö¿ÀÅٽŠII ¼ö¿ëü ±æÇ×Á¦ (Calcium Channel Blockers and Angiotensin II Receptor Antagonists)
|
º¹ÁöºÎºÐ·ù |
214[Ç÷¾Ð°ÇÏÁ¦ ] |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå |
642904870 Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó \1,004 ¿ø/1Á¤(2022.01.01)(ÇöÀç¾à°¡)\1,005 ¿ø/1Á¤(2020.01.01) (º¯°æÀü¾à°¡)
|
|
|
ATCÄÚµå |
Valsartan and amlodipine / C09DB01 |
NDCÄÚµå |
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
|
¼ººÐ / ÇÔ·® |
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
|
÷°¡Á¦ |
¶ó¿ì¸±È²»ê³ªÆ®·ý,
¹Ì°áÁ¤¼¿·ê·Î¿À½º,
»êÈƼź,
½ºÅ׾Ƹ£»ê¸¶±×³×½·,
¿ÀÆĵå¶óÀÌ Èò»ö(OY-S-7223),
Àû»ö40È£,
ÄÝ·ÎÀ̵强ÀÌ»êȱԼÒ,
Å©·Î½ºÄ«¸£¸á·Î¿À½º³ªÆ®·ý,
Ȳ»ö»êÈö
|
|
|
|
|
|
|
|
|
|
Ç× ¸ñ |
³» ¿ë |
|
|
|
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-05-12 |
|
|
|
|
|
|
|
|
|